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Abstract
Background: To further our understanding of the structure and function of HIV-1 integrase (IN)
we developed and characterized a library of monoclonal antibodies (mAbs) directed against this
protein. One of these antibodies, mAb33, which is specific for the C-terminal domain, was found
to inhibit HIV-1 IN processing activity in vitro; a corresponding Fv fragment was able to inhibit HIV-
1 integration in vivo. Our subsequent studies, using heteronuclear nuclear magnetic resonance
spectroscopy, identified six solvent accessible residues on the surface of the C-terminal domain
that were immobilized upon binding of the antibody, which were proposed to comprise the
epitope. Here we test this hypothesis by measuring the affinity of mAb33 to HIV-1 proteins that
contain Ala substitutions in each of these positions. To gain additional insight into the mode of
inhibition we also measured the DNA binding capacity and enzymatic activities of the Ala
substituted proteins.
Results: We found that Ala substitution of any one of five of the putative epitope residues, F223,
R224, Y226, I267, and I268, caused a decrease in the affinity of the mAb33 for HIV-1 IN, confirming
the prediction from NMR data. Although IN derivatives with Ala substitutions in or near the
mAb33 epitope exhibited decreased enzymatic activity, none of the epitope substitutions
compromised DNA binding to full length HIV-1 IN, as measured by surface plasmon resonance
spectroscopy. Two of these derivatives, IN (I276A) and IN (I267A/I268A), exhibited both increased
DNA binding affinity and uncharacteristic dissociation kinetics; these proteins also exhibited non-
specific nuclease activity. Results from these investigations are discussed in the context of current
models for how the C-terminal domain interacts with substrate DNA.
Conclusion: It is unlikely that inhibition of HIV-1 IN activity by mAb33 is caused by direct
interaction with residues that are essential for substrate binding. Rather our findings are most
consistent with a model whereby mAb33 binding distorts or constrains the structure of the C-
terminal domain and/or blocks substrate binding indirectly. The DNA binding properties and non-
specific nuclease activity of the I267A derivatives suggest that the C-terminal domain of IN normally
plays an important role in aligning the viral DNA end for proper processing.
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Background
HIV-1 Integrase (IN)1 is a 32-kDa viral protein that is
required for the insertion of viral DNA into the chromo-
some of the host cell, an essential step in the life cycle of
retroviruses [1-3]. Because of its critical role, IN is as an
attractive target for the design and screening of novel
drugs against AIDS [4]. IN catalyzes the first two steps of
the three-step DNA integration process. In the first step
called processing, IN nicks the 3'-ends of the viral DNA,
releasing two nucleotides from each of the 3'-OH ends. In
the second step, IN catalyzes a concerted cleavage-ligation
reaction in which both 3'-processed viral DNA ends are
joined to the host-cell chromosomal DNA. The IN protein
is composed of three distinct domains: an N-terminal
domain (NTD); a catalytic core domain (CCD); and a C-
terminal domain (CTD) [5-7]. The NTD (residues 1–50)
comprises a three-helix bundle containing a conserved
HHCC motif, which chelates one Zn2+ [8,9]. This region
was shown to promote IN protein oligomerization [10].
The CCD (residues 50–212) contains a conserved
D,D(35)E motif, which comprises the active site of IN and
which binds at least one divalent metal cofactor, Mg2+ or
Mn2+, required for enzymatic activity [11-14]. The CTD
(residues 213–288) is important for binding of viral and
possibly host DNA [15-18]. The isolated CTD adopts an
SH3 fold and forms a dimer in solution [19,20]. However,
it should be noted that only the CCD displays the same
dimer interface in all crystal structures determined to date.
There is considerable variation among CTD interfaces in
crystal structures of two-domain derivates of IN that
include the CTD [21]; some of these interfaces are seen
only across symmetry-related molecules in the crystals.
Various lines of evidence indicate that HIV-1 IN under-
goes a conformational change upon addition of the Mg2+
or Mn2+ cofactor, and that this change promotes preferen-
tial and stable binding to its viral DNAsubstrate [22-24].
We have developed a library of monoclonal antibodies to
HIV-1 IN one of which, mAb33, is specific for the CTD,
but binds tightly only to the apo-enzyme. Binding of
mAb33 prevents the metal-induced conformational
change and inhibits the enzymatic activity of IN. If metal
and substrate DNA are added before the antibody, inhibi-
tion of IN activity is greatly reduced [25]. These observa-
tions are consistent with a model in which the mAb33
epitope becomes inaccessible in the ternary
IN•Metal•DNA conformation. However, we have also
shown that the Fab fragment of mAb33 blocks DNA bind-
ing to the isolated CTD [26]. Therefore, it was conceivable
that this antibody also blocks DNA binding to full length
HIV-1 IN either by competing for the same or overlapping
binding sites, or by distorting or constraining the structure
of the CTD. Because intracellular expression of an scFv
fragment derived from mAb33 blocks HIV-1 replication
[27], its epitope must be accessible in infected cells and
could therefore be a valuable target for developing inhib-
itors for AIDS therapy.
We reported previously that binding of mAb33 restricts
the mobility of six contiguous, solvent accessible residues
in the isolated CTD as determined by nuclear magnetic
resonance (NMR) spectroscopy. We proposed that these
residues, F223, R224, Y226, K244, I267, and I268 (Figure
1A), are included in the epitope for this antibody. Here we
test this hypothesis by measuring the affinity of mAb33 to
HIV-1 IN proteins that contain Ala substitutions in each of
these positions. To gain additional insight into the mode
of inhibition by mAb33 and the role of the CTD in HIV-1
IN activity, we also measured the DNA binding capacity
and enzymatic activities of these Ala substituted proteins.
Results
Expression, purification, and characterization of HIV-1 IN 
proteins
To facilitate our SPR studies it was advantageous to
increase the solubility of IN. The mutations that were
introduced for this purpose encoded proteins with the fol-
lowing additional substitutions: 3CS/F185H, 3CS/F185K,
3CS/F185H/W131D/F139D, and 3CS/F185K/W131D/
F139D. These changes also helped to reduce non-specific
association of the IN proteins with the surface of the bio-
sensor chip. These soluble derivatives were expressed and
purified as described in Materials and Methods. The best
yield of purified soluble protein was obtained with the
3CS/F185H/W131D/F139D derivative: approximately 40
mg per liter of culture, after cleavage of the 6XHis tag and
the final purification step of Heparin column chromatog-
raphy. Although all of the substituted IN proteins dis-
played similar -2 processing activity and mAb33 binding
affinity (data not shown), we elected to utilize the 3CS/
F185H/W131D/F139D-encoding construct for further
mutagenesis studies because this protein exhibited the
highest solubility. This hexa-substituted, soluble form of
the HIV-1 IN protein was designated soluble IN (sIN).
Several of the substitutions introduced into the CTD of
sIN resulted in derivatives with decreased solubility as
well as lower affinity for the Heparin column compared to
the sIN protein. For this reason, the 6XHis tag was left on
sIN and the CTD substituted sIN proteins for the studies
presented here. The yield of purified His-sIN from a 1L
expression culture was 80 mg. There were no significant
differences observed between sIN and His-sIN in their
ability to bind mAb33 or DNA, and the proteins had com-
parable catalytic activities (data not shown).
Rationale for amino acid substitutions
The binding of mAb33 was previously reported to reduce
mobility of contiguous residues on the surface of the β-
strands of the isolated CTD [28]. It was proposed that
these residues, F223, R224, and Y226 on β1, K244 on β2,Retrovirology 2006, 3:34 http://www.retrovirology.com/content/3/1/34
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Ala substitution of residues in the NMR-determined epitope of mAb33 decrease antibody binding Figure 1
Ala substitution of residues in the NMR-determined epitope of mAb33 decrease antibody binding. (A) Model of 
the HIV-1 CTD dimer. Left panel: The NMR-determined SH3-fold structure of the CTD is displayed with one subunit colored 
in yellow and the other in blue. DNA binding residues E246, K264, K266, and R262 are shown in ball-and-stick representation 
and labeled with black lettering. Residues of the putative mAb33 epitope, as determined by NMR techniques [28], are displayed 
in green space filling representation. K244 is shown in grey, as it is unlikely to be a critical component of the mAb33 epitope 
(see Panel B). The long arrow points to residue W243 at the interface between subunits in this NMR dimer of the CTD which 
forms a "saddle" with both K264 residues extending into the cleft proposed to bind DNA [19]. Right panel: An orthogonal view 
rotated 90 degrees about the displayed axis. This view shows residues known to be involved in DNA binding on one face of 
the subunit and adjacent to the mAb33 epitope. (B) ELISA data for CTD substituted HIV-1 sIN proteins and their interactions 
with mAb33. A high binding microtiter plate was coated with 50 ng of antigen (sIN or one of the Ala substituted sIN proteins) 
and incubated overnight at 4°C. The plates were then blocked with bovine serum albumin, washed, and incubated with the 
mAb33 1° antibody which was serially diluted (2-fold) from a starting concentration of 250 ng per well. A standard ELISA pro-
tocol was then followed using an alkaline phosphatase conjugated 2° antibody against the kappa chain. The relative binding effi-
ciency of mAb33 to the IN proteins was determined by measuring the absorbance at 405 nm.Retrovirology 2006, 3:34 http://www.retrovirology.com/content/3/1/34
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and I267 and I268 on β5 (Figure 1A) comprise the mAb33
epitope. To determine if these amino acids are important
for mAb33 recognition, alanine-scanning mutagenesis
was used. Residues R262 and W243, which are adjacent to
the putative antibody binding site and could be affected
by antibody binding, were also changed to produce Ala
substituted derivatives. The R262 residue has been impli-
cated in DNA binding [29] and modeling studies sug-
gested that the close proximity of R262 to the mAb33
binding site might account for decrease binding of IN to
DNA in the presence of the corresponding Fab fragment,
Fab33 [28]. W243 has been implicated in CTD dimer
interactions and is adjacent to the putative epitope resi-
due, K244. Comparison of residues protected from pro-
tease digestion by Fab33 and another CTD-specific
monoclonal, Fab32, revealed that Fab33 interacts with
I267 and I268, whereas Fab32, which has no effect on
DNA binding, does not [30,31]. We therefore chose to
analyze these residues in greater detail by generating both
of the single substitutions, I267A and I268A, as well as the
doubly substituted sIN protein, I267A/I268A.
Substitution of putative epitope residues affects antibody 
binding
The relative binding affinities of mAb33 to sIN and the
Ala substituted sIN proteins were assessed by the enzyme-
linked immunosorbent assay (ELISA). Alanine substitu-
tion of five of the six residues comprising the putative
mAb33 epitope resulted in a significant reduction in the
binding affinity of mAb33 (Figure 1B). Interestingly, the
greatest reductions were seen with Ala substitution of the
hydrophobic residues, Y226A, I267A, and I268A. The
R224A, and F223A sIN proteins were less seriously com-
promised for mAb33 binding. The K244A derivative was
largely unaffected in mAb33 binding, consistent with the
variable results observed in our previous NMR studies
[28]. This residue is unlikely therefore to play a direct role
in antibody binding. The non-epitope substitution R262A
derivative binds mAb33 as well as the parental protein
sIN, as expected from previous NMR studies [28], while
W243A, which may be involved in dimer interactions
[21], is compromised for antibody binding.
As a control, sIN and the Ala substituted sIN proteins were
also analyzed for their abilities to bind NTD-specific
mAb17 and CCD-specific mAb4 [31,32]. No significant
differences were observed in the abilities of the substi-
tuted derivatives to interact with these monoclonal anti-
bodies as compared with sIN (data not shown). These
data indicate that the NTDs and CCDs of the derivative
proteins are not grossly disordered.
Effect of substitutions in epitope and non-epitope residues 
on IN activity
The effects of the CTD substitutions on enzymatic func-
tion were determined by assaying for the processing and
joining activities using model duplex oligonucleotides
that represent the viral U5 DNA end [2]. Results from
these experiments, summarized in Figure 2, show that the
proteins with substitutions in the mAb33 epitope retained
35% or more of the processing activity observed with the
parental sIN. Proteins with substitutions in the non-
epitope residues W243A and R262A were more defective.
Only the R224A and K244A derivatives retained signifi-
cant joining activity compared to the sIN, indicating that
the epitope residues are important for protein function.
The data in Figure 3 show that the processing products
obtained with the I267A derivative were strikingly differ-
ent from the parental sIN. This IN protein appears to have
lost specificity for the -2 position and behaves instead as a
highly active, non-specific nuclease. The I267A/I268A
derivative is also less specific, but its nuclease activity
appeared to diminish with distance from the 3'-end. As
these activities were blocked by addition of an HIV-1 IN
inhibitor [33], as was the sIN control, they are not caused
by nuclease contamination of the derivative proteins.
These results indicate that determinants in the CTD affect
the specificity of catalysis by the CCD.
Effect of substitutions in epitope and non-epitope residues 
on DNA binding
Surface plasmon resonance spectroscopy was used to
study the interactions of sIN and derivative proteins with
model viral DNA substrates that represent a blunt U5 LTR
end, a processed U5 LTR end, and host target DNA. It was
reported that divalent cations, such as Mg2+, Mn2+, and
Ca2+, can stimulate the binding of HIV-1 IN to model viral
DNA substrates [22]. Divalent cations have been shown to
induce a conformational change in the enzyme [25],
Enzymatic Activity of HIV sIN and the CTD substituted sIN  proteins Figure 2
Enzymatic Activity of HIV sIN and the CTD substi-
tuted sIN proteins. Processing (solid bars) and joining 
(open bars) activities of the sIN derivatives are shown rela-
tive to that of sIN, whose activity is set at 100%. Assay condi-
tions are described in Materials and Methods.Retrovirology 2006, 3:34 http://www.retrovirology.com/content/3/1/34
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which might allow it to recognize and bind to viral DNA
ends preferentially. To determine if the substitutions in
sIN affected the metal-induced stimulation and binding
kinetics of the enzyme, we examined the effect of Mg2+ on
the association of these proteins with DNA. Our results
with the parental sIN protein (Table 1) are consistent with
those previously published by Yi et al. [28]; sIN shows a 2-
fold increase in binding affinity for the unprocessed viral
DNA in the presence of Mg2+, indicating that the solubil-
ity-enhancing substitutions do not alter the conforma-
tional change associated with viral DNA binding and/or
recognition.
DNA binding data for the sIN derivative proteins are pre-
sented in Table 2. The results show that most proteins
exhibit a modest preference for the blunt viral DNA end,
compared with processed viral DNA or target DNA. The Kd
values for proteins containing F223A, R224A, Y226A, or
K244A substitutions are comparable to that of the paren-
tal sIN with respect to all the model DNA substrates. These
data indicate that the substituted residues do not play a
significant role in DNA binding. Residue W243 which is
not part of the mAb33 epitope but lies adjacent to it,
shows about a 2-fold decrease in binding affinity com-
pared with sIN. W243 is believed to play a role in a CTD
dimer interaction that may be compromised in the
W243A derivative [21]. Kinetic parameters could not be
determined for the R262 protein because binding to the
DNA sensor chip was barely detectable, as expected [29].
This result indicates that even though DNA interactions
may occur with other domains in the protein, they are not
tight enough to produce a measurable SPR signal with this
protein. From this control we can conclude that the data
in Table 2 comprises a valid readout for the contribution
of CTD residues to interaction with DNA.
The most significant change was observed with the I267A
and I267A/I268A substituted proteins, which showed
more than a 2-fold increase in binding affinity compared
with sIN. This difference results mainly from a decrease in
the off rates. The additional I268A substitution did not
appear to alter the binding affinity of I267A. Furthermore,
unlike sIN and the other derivatives, I267A and I267A/
I268A have very similar Kd values for model viral and host
DNA. Wild type IN and sIN both display a characteristic
biphasic IN-DNA dissociation which is detected by SPR as
a fast phase followed by a much slower dissociation. The
dissociation kinetics of the I267A and I267A/I268A deriv-
atives with all three model DNA substrates were altered
compared to sIN; the fast dissociation was absent and
only the slow dissociation kinetics were observed (data
not shown).
Discussion
We have shown that mAb33, which targets the CTD of
HIV-1 IN, is an effective inhibitor of the enzyme in vitro
[27,32,34,35], and that intracellular expression of the cog-
nate Fv fragment blocks HIV-1 replication (27). Under-
standing the relationship between the structure and
function of HIV-1 IN is important for the development of
potent drugs that target this enzyme. Most small molecule
inhibitors developed to date target the active site in the
catalytic core domain; the CTD has been overlooked as a
target for drug design. Because knowledge of how binding
of mAb33 to its epitope inhibits IN activity may reveal a
valuable drug target, we have examined this interaction in
some detail. Our previous studies have uncovered an
unexpectedly complex mechanism. We found that mAb33
binding occurs only in the absence of the metal cofactor
and such binding prevents a conformational change in
the full-length protein that normally occurs upon cofactor
binding and which is required for enzyme activity [, ].
Subsequent studies with the Fab fragment of mAb33 and
the isolated CTD showed that binding rendered this
domain resistant to proteolysis and also blocked DNA
binding.
We have considered three, non-exclusive hypotheses for
the mechanism of inhibition of full length HIV-1 IN by
mAb33: 1) mAb33 binding blocks DNA binding, either
because the binding sites overlap or the binding pocket is
distorted, 2) mAb33 binds to residues whose availability
Non-specific nuclease activity of I267A sIN derivatives Figure 3
Non-specific nuclease activity of I267A sIN deriva-
tives. Reaction conditions are described in Materials and 
Methods. Bl represents a blank reaction in which the enzyme 
was omitted. (-) indicates duplicate reactions in which the 
Merck HIV-1 inhibitor L-708,906 was absent. Either 10 or 
100 µM of the L-708,906 inhibitor was added as indicated. 
These concentrations of inhibitor are expected to affect the 
processing as well as the joining activity of wild type HIV-1 IN 
[33].Retrovirology 2006, 3:34 http://www.retrovirology.com/content/3/1/34
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are critical for IN function, and 3) mAb33 binding has
detrimental long-range or conformational effects. Our
previous NMR studies, supported by results from the
ELISA assays summarized in Figure 1B, have identified
five key components of the epitope for this antibody. Such
identification and analysis of Ala substituted derivatives
have allowed us to test some of the predictions of these
hypotheses.
Data summarized in Table 2 show that binding of DNA by
the full-length IN protein is not reduced by substituting
any one of the residues in the mAb33 epitope with Ala.
These results show that none of these residues is abso-
lutely required for substrate binding. It is unlikely, there-
fore, that there is an overlap of binding sites for substrate
with mAb33, as proposed in hypothesis 1. It remains pos-
sible, however, that mAb33 hinders DNA access to nearby
residues that are essential for substrate binding. The
mAb33 epitope is in close proximity to amino acids E246,
R262, K264, and K266, which were shown by mutagene-
sis and various DNA binding assays to be important for
substrate binding [18,20,29,36,37]. Unfortunately, the
importance of this proximity is difficult to evaluate
because the manner in which DNA interacts with the CTD
is not yet known.
It was first suggested that DNA might bind in a "saddle"
between two CTDs that form a dimer in the NMR-deter-
mined structure of this domain (see Figure 1A, left)
[19,20]. However, as such a saddle is not observed in the
two-domain crystal structure of HIV IN (50–288) its sig-
nificance to DNA binding is unclear [21]. Substrate DNA
has also been proposed to bind to a different face of the
CTD, where several known DNA binding residues cluster
(see Figure 1A, right) [38,39]. Modeling studies by Zhu et
al. [39] have identified residues in the CTD that might be
involved in DNA binding to this region. Of these, residues
K244 and I267 are predicted to form hydrogen bonds
with the substrate DNA molecule in their model. Because
we show that Ala substitution of either of these residues
has no effect on DNA binding (Table 2), such hydrogen
bonding cannot be essential for this function. Other
recent studies have mapped the binding site for an IN
inhibitor, pyridoxal 5' phosphate (PLP), to a region of the
CTD close to that of the mAb33 epitope. These studies
show that K244 is in contact with the PLP inhibitor, which
is active in the low micromolar range [40,41]. However, as
already noted, because our data (Table 2) show that Ala
substitution of K244 does not reduce DNA binding, we
suggest that PLP may inhibit HIV-1 IN by affecting the
conformation or flexibility of the DNA binding pocket,
Table 1: The effect of metal ions on the kinetic parameters of HIV-1 sIN binding to DNA substrates
U5-End U5-End Cut Target
kon 105 M-1 s-1 koff 10-3 s-1 Kd (nM) kon 105 M-1 s-1 koff 10-3 s-1 Kd (nM) kon 105 M-1 s-1 koff 10-3 s-1 Kd (nM)
sIN 1.7 ± 0.1 1.0 ± 0.1 5.9 ± 0.7 1.1 ± 0.1 1.3 ± 0.1 11.8 ± 1.4 1.0 ± 0.1 1.6 ± 0.2 16.0 ± 2.6
sIN no Mg 1.9 ± 0.2 2.1 ± 0.1 11.1 ± 1.3 2.7 ± 0.2 2.0 ± 0.1 7.4 ± 0.7 3.5 ± 0.2 2.1 ± 0.1 6.0 ± 0.7
The model U5 end biotin-labeled substrate (see Experimental Procedures) was immobilized on a SA chip. BIAcore data were collected by injecting 
different concentrations of sIN, ranging from 50 to 300 nM dimers, at a flow rate of 30 µL/min. No Mg2+ ions were achieved by eliminating MgCl2 
from the running buffer and including 0.5 mM EDTA in the running as well as the dilution buffer. The dissociation constant was calculated from the 
ratio of the average of the off and the apparent on rates. All injections were done at 25°C.
Table 2: Kinetic parameters for HIV-1 sIN substituted proteins binding to DNA substrates
U5-End U5-End Cut Target
kon 105 M-1 s-1 koff 10-3 s-1 Kd (nM) kon 105 M-1 s-1 koff 10-3 s-1 Kd (nM) kon 105 M-1 s-1 koff 10-3 s-1 Kd (nM)
sIN 1.7 ± 0.1 1.0 ± 0.1 5.9 ± 0.7 1.1 ± 0.1 1.3 ± 0.1 11.8 ± 1.4 1.0 ± 0.1 1.6 ± 0.2 16.0 ± 2.6
F223A 2.1 ± 0.2 1.1 ± 0.1 5.2 ± 0.7 1.1 ± 0.2 1.6 ± 0.2 14.5 ± 3.2 0.8 ± 0.1 2.5 ± 0.2 31.3 ± 4.7
R224A 1.3 ± 0.2 0.9 ± 0.1 6.9 ± 1.3 1.1 ± 0.2 1.2 ± 0.2 10.9 ± 2.7 0.9 ± 0.2 1.5 ± 0.2 16.7 ± 2.3
Y226A 1.2 ± 0.2 1.0 ± 0.1 8.3 ± 1.6 0.8 ± 0.1 0.6 ± 0.1 7.5 ± 1.6 0.6 ± 0.1 0.7 ± 0.1 11.7 ± 2.6
I267A 0.9 ± 0.1 0.2 ± 0.1 2.2 ± 1.1 1.0 ± 0.1 0.3 ± 0.1 3.0 ± 1.0 0.8 ± 0.1 0.3 ± 0.1 3.8 ± 1.6
I267A/I268A 0.8 ± 0.1 0.2 ± 0.1 2.5 ± 1.3 0.9 ± 0.1 0.3 ± 0.1 3.3 ± 1.2 0.7 ± 0.1 0.2 ± 0.1 2.9 ± 1.5
K244A 1.9 ± 0.2 1.2 ± 0.2 6.3 ± 1.2 0.9 ± 0.1 1.0 ± 0.2 11.1 ± 2.5 0.9 ± 0.1 1.2 ± 0.2 13.3 ± 2.7
W243A 0.5 ± 0.1 0.7 ± 0.1 14.0 ± 3.4 0.8 ± 0.2 0.9 ± 0.1 11.3 ± 0.3 0.9 ± 0.1 1.4 ± 0.1 15.6 ± 2.1
R 2 6 2 A - -N D - -N D - -N D
Three different model biotin-labeled substrates were immobilized on the surface of a SA chip as described in Experimental Procedures. BIAcore 
data were collected by injecting different concentrations of sIN, ranging from 50 to 300 nM dimers, at a flow rate of 30 µL/min. All data were 
collected using buffer containing 5 mM MgCl2. The dissociation constant was calculated from the ratio of the average of the off and the apparent on 
rates. All injections were done at 25°C. ND, kinetic parameters could not be determined due to low binding efficiency.Retrovirology 2006, 3:34 http://www.retrovirology.com/content/3/1/34
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rather than competing for the DNA binding site. Taken
together, results from our analyses of the Ala derivatives
fail to provide evidence that mAb33 inhibits the activity of
full-length IN by competing directly for critical DNA bind-
ing residues, but leaves open the possibility that DNA
binding could be blocked indirectly.
In the absence of knowledge of the exact spatial organiza-
tion of CTDs within an active IN-DNA complex we cannot
exclude the possibility that some of our Ala substitutions
disrupt important domain interactions, and that this con-
tributes to the decreases in enzymatic activity observed
with these derivatives (Figure 2). Furthermore, although
binding of the antibody to epitope residues might not be
expected to produce the same phenotype as substituting
epitope residues, blocking determinants that are essential
for protein-protein interactions, or critical long-range
effects, could also account for inhibition by mAb33 (i.e.
hypotheses 2 and 3 above). Consideration of these possi-
ble mechanisms awaits a more detailed knowledge of the
structure of a functional IN-DNA complex.
Finally, one striking result from our analyses deserves spe-
cial comment. Because the CTD is known to be critical for
substrate binding by integrase [reviewed in [42]], the find-
ing that some of our substitutions actually increased the
affinity of full-length IN for DNA was quite unexpected.
These proteins, I267A and I267A/I268A, exhibit both
increased DNA binding affinity (Table 2), and an absence
of the initial faster dissociation phase that is characteristic
of the biphasic pattern normally observed with IN. Fur-
thermore, tighter binding was not accompanied by an
increase in -2 processing but rather by an increase in non-
specific DNA cleavage with these derivatives (Figure 3). A
rapid association with DNA, coupled with the fast dissoci-
ation phase seen with wild type IN might be important for
positioning the viral DNA ends for processing; the later,
slow dissociation may represent a stable IN-DNA complex
that is required for formation of the pre-integration com-
plex. The aberrant properties of the I267A derivatives are
consistent with such a model, in which the CTD normally




Construction of plasmid pET28b, encoding 6XHis – HIV-
1 IN – 3CS (C56S, C65S, C280S), was previously reported
[26]. Using this plasmid backbone, site-directed mutagen-
esis (QuikChange Site-Directed Mutagenesis Kit, Strata-
gene) was utilized to introduce mutations encoding the
amino acid substitutions F185H and/or F185K, as well as
W131D and F139D, which were previously found to
increase HIV-1 IN solubility [31]. The four DNA con-
structs specified the following substitutions: 3CS/F185H,
3CS/F185K, 3CS/F185H/W131D/F139D, and 3CS/
F185K/W131D/F139D. The constructs were confirmed by
DNA sequencing. Characterization of the substituted HIV-
1 IN proteins confirmed that the 3CS/F185H/W131D/
F139D derivative was the most soluble among them, and
had properties comparable to the wild-type protein. This
hexa-substituted HIV-1 IN protein was hereafter called
"soluble IN," or sIN. The sIN-expressing backbone plas-
mid was then utilized for subsequent site-directed muta-
genesis, as per the manufacturer's (Stratagene)
instructions, to generate the following CTD substituted
full-length sIN derivatives: F223A, R224A, Y226A,
W243A, K244A, R262A, I267A, I268A, and I267A/I268A.
The 6XHis-tagged proteins were expressed in Escherichia
coli BL21(DE3) and purified as follows: cells were grown
to an OD600 of 0.8 with shaking at 37°C, induced with 0.2
mg/ml IPTG for 3 hr, and pelleted. The cell pellets were
resuspended in 20 mM HEPES-NaOH, 0.5 M NaCl, pH
7.4 containing 1 mM PMSF and 1 µg/ml each of pepstatin,
leupeptin, and aprotinin. Following the addition of 1 mg/
ml lysozyme to the cell sample and incubation at 25°C
for 30 min, the preparation was sonicated for 100 sec on
ice. The resulting lysate was subjected to centrifugation at
10,000 g. The supernatant fraction was then applied to a
HiTrap Chelating HP column (Amersham Pharmacia Bio-
tech) that had been loaded with Ni2+, as per the manufac-
turer's protocol. Following sample application, the
column was first washed with 10 column volumes of
binding buffer (20 mM HEPES-NaOH, 0.5 M NaCl, pH
7.4) and then with 5 column volumes of binding buffer
containing 50 mM imidazole. The 6XHis-tagged HIV-1 IN
proteins were eluted with 10 column volumes of binding
buffer containing 0.5 M imidazole. Following elution
from the Ni2+ chelating column, the proteins were washed
and concentrated using Amicon Ultra centrifugal filters
with a 10 kDa cutoff (Millipore) into storage buffer (50
mM HEPES-KOH, 0.5 M KCl, pH 7.4 containing 0.1 mM
EDTA, 1 µg/ml each of pepstatin, leupeptin, and apro-
tinin, and 40% glycerol). The samples were then frozen
quickly and stored as aliquots at -80°C. The proteins were
thawed on ice immediately prior to use.
Enzyme-linked immunosorbent assay (ELISA)
The binding affinities of anti-HIV-1 IN monoclonal anti-
bodies were determined as previously described [28].
Minor modifications to the experimental conditions are
described in the relevant figure legend.
Enzymatic activity assays
For the in vitro processing reactions, 1 µM of each enzyme
was incubated with 1 µM 32P-labeled 21 base pair model
viral DNA substrate for 1 hr in HEPES Buffer (pH 7.5) as
described previously [2]. Processing was measured by
quantifying the -2 cleavage product after exposure of the
radioactive gel using a Fuji imaging system. The in vitroRetrovirology 2006, 3:34 http://www.retrovirology.com/content/3/1/34
Page 8 of 10
(page number not for citation purposes)
joining activity was measured by using a modified radio-
active-biotin assay developed for ASV integrase [43]. The
donor, comprising the same 21 base pair U5 viral DNA
substrate, was labeled on the 5'-end of the strand to be
processed. The target DNA comprised a 28 base pair
duplex biotinylated on each 3'-end. Two µM of enzyme
was incubated with 1 µM of 32P-labeled donor DNA in
reaction buffer (25 mM HEPES, pH 7.5, 25 mM KCl, 2
mM 2-mercaptoethanol, 10 mM MnCl2) for 15 min on
ice. The target DNA was then added to a final concentra-
tion of 12 µM, the mixture was incubated for an addi-
tional 15 min on ice, and then transferred to a 37°C
incubator. After 2 hrs, the reaction was quenched by the
addition of EDTA, and 30 µL of streptavidin-agarose
beads (Invitrogen) was added to each reaction, which was
incubated at room temperature for 1 hr with gentle mix-
ing to capture the biotin-labeled products. The slurry was
subjected to centrifugation and the pellet washed 4 times
with wash buffer (PBS, 0.05% SDS, 1 mM EDTA). After
the final wash, the pellet was resuspended in 200 µL PBS
and the radioactivity bound to the beads was determined
by liquid scintillation counting.
DNA binding assay
Surface Plasmon Resonance (SPR) spectroscopy was used
to measure the binding affinities of IN to DNA using a
BIAcore 1000 instrument. The sequence of the three
model duplex DNA substrates used correspond to those
previously published by Yi et al. [26]. The 5'-end of one
strand from each duplex was labeled with biotin to facili-
tate immobilization to the surface of a streptavidin-coated
biosensor chip. The model substrates represent the
unprocessed 5'-LTR end, the processed 5'-LTR end, and
the host-target DNA; the substrates comprise the follow-
ing sequences in which the conserved sub-terminal CA/
GT bases in the viral LTR are underlined:
(1) U5-END (21 bp viral DNA end substrate): top strand,
5'GTGTGGAAAATCTCTAGCAGT-3'; bottom strand,
BIOTIN-GCACACCTTTTAGAGATCGTCA-5'
(2) U5-END CUT (processed viral DNA end): top strand,
5'-GTGTGGAAAATCTCTAGCA-3'; bottom strand,
BIOTIN-GCACACCTTTTAGAGATCGTCA-5'
(3) TARGET (non-viral DNA sequence): top strand, 5'-
CCGCGATAAGCTTTAATGCGG-TAG-3'; bottom strand,
BIOTIN-CGGCGCTATTCGAAATTACGCCATC-5'.
All oligonucleotides were gel-purified, heated to 94°C in
HBS buffer, and cooled slowly to room temperature,
allowing proper hybridization with the complementary
strand prior to immobilization on the sensor chip. The
surface of the streptavidin chip was primed with two injec-
tions of 10 µl of 0.035% (w/v) SDS to remove weakly
bound streptavidin. Sufficient hybridized DNA was
injected to give approximately 250–300 response or reso-
nance units (RU) after washing with 10 µl of 0.035% SDS.
20 µl of biotin was then injected to block the free binding
sites and to decrease non-specific binding.
The running buffer consisted of 10 mM HEPES (pH 7.5),
150 mM NaCl2, 1 mM DTT, 5 mM MgCl2, and 0.005%
surfactant P20 (bufferA). All proteins were dialysed in
buffered A and quantified using Bradford assay with BSA
as a standard.
Sensograms were obtained for each IN derivative by
injecting various concentrations of protein, ranging from
50 to 150 nM with respect to the dimer form of IN (the
predominant form under these conditions), at a flow rate
of 30 µL/min. The surface of the sensor chip was regener-
ated after each injection of protein by washing with 10 µL
of 0.035% SDS, which removed only the bound protein
and did not affect the amount of DNA immobilized on
the surface of the chip. Data from each sensogram were
analysed using the Bioevaluation program. IN shows a
characteristic biphasic dissociation as reported by Yi et al.
[26]. To obtain the kinetic rate constant for dissociation
(koff or Kd) and the apparent association (kon or ka), the
real time data were fitted individually to generate the
apparent dissociation constant (Kd = koff/kon). The slower
phase of the biphasic dissociation was fitted to obtain koff.
Based on published data, it was assumed that the IN binds
as a dimer to a single immobilized DNA end to yield a sta-
ble complex.
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